Economic impact of recurrent respiratory papillomas in a UK adult population. Issue 7 (18th May 2016)

• Record Type: Journal Article
• Authors: Harrison, A; Montgomery, J; Macgregor, F B
• Is Part Of: Journal of laryngology & otology. Volume 130:Issue 7(2016)
• Page Start: 645
• Page End: 649
• Publication Date: 2016-05-18
• Subjects: Papilloma, -- Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, -- Recurrent Respiratory Papillomatosis, -- Cost Of Illness; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1017/S0022215116001201
• Languages: English
• ISSNs: 0022-2151

Abstract

Abstract: Objective: To calculate the financial burden of recurrent respiratory papilloma. This study is UK-based, where up until now no financial estimates have been calculated for this group of patients. Background: Recurrent respiratory papilloma is caused by the human papilloma virus (subtypes 6 and 11). The burden for the patient and the healthcare system is significant given the recurrent nature of the disease. Methods: Data were collected, using a questionnaire completed during routine clinical follow up, from a single centre managing recurrent respiratory papilloma in Glasgow, Scotland. Cost information was sourced from the Scottish Government's Information Services Division. Results: Fourteen patients with active recurrent respiratory papilloma between 2013 and 2014 were identified. The direct measurable cost to NHS Greater Glasgow and Clyde amounted to £107 478. Conclusion: Recurrent respiratory papilloma is a benign condition, but the financial implications of diagnosis are significant. Recurrent respiratory papilloma has a natural history of relapse and remission, and patients may require healthcare input over a period of several years.